Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 9989)

ANNOUNCEMENT

PROPOSED AMENDMENTS TO THE ARTICLES

Tacabsz Ha **Company**) . . . a R. 13.51(1) f R. Stock Exchange) (T S c Exc a f H Rules). L d(T C a c d 2023 F Ex a d a G a M , A S a C a M a d H S a d 'C a M D c b 15, 2023, A c f A c a f C a d a d b d a d b c ff c (Articles). A a a T bad fd c (Board) f C a a c d fd d f d a f d f Shareholders) a d A c (Proposed Amendments to the Articles). O F b a 14, 2023, S a C c (State Council) f P 'R b c f C a (PRC) d D c f S a C c R a C a (《國務院關於廢止部分行政法規和文件 c c d ab 的決定》)(Decision), d C a (《國務 院關於股份有限公司境外募集股份及上市的特別規定》) . db A. 4, 1994. O F b a 17, 2023, C a S c d T a Ad a M a f O a Off R a d TaAd a Ma. fO a Off ad C a (《境內企業境外發行證券和上市管理試行辦法》)(a d L b D **Trial Measures**) ada.d

I a f Mada P f C a L O a (《關於執行 到境外上市公司章程必備條款 的通知》). T D c a d T a M a (c c , New PRC Regulations) a b ff c c Mac 31, 2023.